Investigators reported that higher levels of childhood plasma CXCL10, IL6 and IL33 were associated with increased odds of belonging to a Persistently Low forced expiratory volume in one second (FEV1) trajectory from ages 8 to 30. The study used previously derived latent profile trajectories of FEV1 and modelled the two lowest trajectories — Persistently Low and Below Average — as outcomes. Logistic regression showed that per standard-deviation increases in plasma CXCL10 and IL6 were associated with odds ratios of 1.29 (95% CI 1.03, 1.57) for Persistently Low trajectory; IL33 had an OR of 1.23 (95% CI 1.04, 1.44). These protein associations were observed in childhood samples collected at ages 7–9. The cohort and timing place the biomarker measures before the measured lung function decline into early adulthood, strengthening temporal inference within observational limits.
Short sentence: proteins tracked with low lung growth. The authors noted a pattern of persistent systemic inflammation markers predicting a disadvantageous lung function course, while other tested biomarkers did not show similar signal. The study team therefore framed these proteins as candidate molecular markers linking early-life biology to long-term pulmonary outcomes.
The authors tested nine blood-derived measures of epigenetic age acceleration (EAA) as exposures but found little evidence that EAA metrics predicted membership in either the Persistently Low or Below Average FEV1 trajectories. Epigenetic clocks were measured in childhood (ages reported in the source), yet associations did not emerge in the logistic regression models used. The study therefore differentiates between proteomic senescence-associated signals and DNA methylation-derived EAA in relation to long-term lung function, with only the protein signals showing robust associations in this dataset.
The cohort approach isolated molecular signals present in childhood. That design matters because EAA measures might change later in life; the source did not report associations at later ages, and the authors did not find childhood EAA to be a predictor in this analysis.
To probe causality the team implemented bidirectional one-sample Mendelian randomisation (MR). MR provided little evidence that genetically predicted plasma proteins (CXCL10, IL6, IL33) increase the risk of membership in lower FEV1 trajectories. In contrast, MR analyses indicated that lower genetically proxied childhood FEV1 predicted higher plasma CXCL10 measured at ages 9 (β -0.34; 95% CI -0.65, -0.03) and at age 24 (β -0.38; 95% CI -0.67, -0.08), as reported in the source. This pattern suggests possible causal flow from impaired lung development or function to persistent elevation of CXCL10, rather than the reverse.
The authors emphasised that MR results were not strong for proteins causing low trajectories, but the genetic instrument for childhood FEV1 showed an association with later CXCL10, pointing toward persistent systemic inflammation as a downstream consequence of low lung function.
The analysis used logistic regression to estimate odds of lower lung function trajectory membership per unit increase in biomarker exposures; age windows for measurement and trajectory derivation were aligned to childhood and early adulthood (FEV1 trajectories spanned ages 8–30). Exposures included thirteen senescence-associated plasma proteins measured at ages 7–9 and nine epigenetic age acceleration measures derived from blood sampled in the same period. The cohort was ALSPAC (Avon Longitudinal Study of Parents and Children). The study team combined conventional epidemiological methods with bidirectional one-sample MR to interrogate directional relationships between biomarkers and lung function.
Short clear point: exposures were childhood proteomic and epigenetic markers; outcomes were long-term FEV1 trajectories. The source did not provide details beyond these methods in the abstract, and full-method specifics are in the underlying preprint and supplementary materials referenced by the authors.
This report is a preprint and has not undergone peer review; the authors explicitly state that the findings should not yet guide clinical practice. The ALSPAC informed consent framework restricts open public data deposition — supporting data are available on request under an approved proposal number. The source did not report certain methodological specifics in the abstract (for example, full covariate adjustment sets and instrument strength metrics for MR); readers must consult the full manuscript and supplementary material for those details.
Remaining clinical questions include whether modulation of IL33 can alter lung function trajectories and whether persistent systemic inflammation represents a mechanistic pathway linking early low FEV1 to later multimorbidity. The authors recommended targeted research to test IL33 as a potential therapeutic target and urged replication in independent cohorts. These are concrete next steps documented in the source rather than speculative claims.
Limitations stated by the study team encompass the preprint status, the need for replication, and the constrained public availability of individual-level data. The study closes on these unresolved items and specific research priorities, rather than a generalised wrap-up statement.